年销数百亿美元的“减肥神药”陷致盲风波

中国经营网
Nov 21

近日,美国FDA发布通告称,使用GLP-1 RAs(GLP-1受体激动剂类)产品可能增加非动脉性前缺血性视神经病变(NAION)的风险。NAION是一种罕见的疾病,可能导致单眼急性、无痛、视力下降,包括永久性视力丧失。美国FDA要求所有GLP-1 RAs药物的申请持有人在标签上增加风险警示信息。这一消息在社交媒体平台上引起广泛热议。  GLP-1 RAs被广泛用于治疗2型糖尿病患者或减轻超重并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10